# BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

> **NCT02719171** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 185 (actual)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** risankizumab
- **DRUG:** placebo for risankizumab

## Key facts

- **NCT ID:** NCT02719171
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-05
- **Final completion:** 2017-08
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2019-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02719171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02719171, "BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02719171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*